Celldex Therapeutics (CLDX) Financials

Celldex Therapeutics (NASDAQ: CLDX) continues to look like a well-capitalized clinical-stage biotech, but one that is still burning a large amount of cash while waiting for product revenue to become meaningful. The company ended Q1 2026 with a very large cash and investment balance, but quarterly losses remain heavy and operating cash outflow is substantial. For retail investors, the key takeaway is that Celldex appears to have time on its side financially, but it is still highly dependent on future clinical and commercial execution.

• Strong liquidity position: Q1 2026 cash and short-term investments totaled about $451.5 million, which is a solid war chest for ongoing R&D.
• Debt is not a major issue: Total liabilities were only about $55.0 million versus $456.2 million in equity, leaving the balance sheet relatively clean.
• Very large equity base: Total common equity stood at roughly $456.2 million, reflecting continued capitalization support for the business.
• Investment portfolio helped offset losses: In Q1 2026, the company generated $72.1 million in net cash from investing activities, driven by sales/maturities of investments.
• Cash balance improved sequentially: Cash and equivalents rose to $35.7 million from $36.0 million in Q3 2025, while the company also held substantial short-term investments.
• Revenue is still immaterial: Q1 2026 revenue was only $15,000, so Celldex is still effectively operating as a pre-commercial biotech.
• Operating losses remain large: Q1 2026 net loss was $78.7 million, only slightly improved from $81.3 million in Q4 2025.
• R&D remains the biggest expense: Research and development spending was $73.0 million in Q1 2026, showing the company is still heavily focused on pipeline advancement.
• Operating cash burn is significant: Net cash used in operating activities was $65.6 million in Q1 2026, which is a high burn rate relative to current operations.
• Revenue trend is inconsistent and very small: Quarterly revenue has fluctuated from near-zero to only a few million dollars over the last several years, offering little help in covering expenses.

Trend analysis over the last four years: Celldex’s balance sheet has strengthened materially in the sense that it still has ample liquidity and low liabilities, but the income statement and cash flow statement continue to show a company spending aggressively to advance its pipeline. Compared with 2023, quarterly net losses and operating cash outflows have generally improved somewhat, but the company is still not close to breakeven. The biggest positive is financial runway; the biggest risk is whether that runway is enough to get to a meaningful value-driving catalyst before cash burn forces more dilution or fundraising.

Bottom line: CLDX looks financially stable for now, with plenty of cash and investments, but it remains a classic high-risk biotech story. Investors are paying for pipeline optionality rather than current earnings power.